06.04.2020 Elixirgen Therapeutics Concludes pre-IND Meeting with FDA for its COVID-19 Vaccine Candidate EXG-5003
06.04.2020 FDA Approves Elixirgen Therapeutics IND Application for Therapy for Telomere Biology Disorders with Bone Marrow Failure